Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection

A technology of ganoderma acid and dihydroxyl, used in ganoderma 7,9(11),24-trien-3-one 15,26-dihydroxy-stane triterpene in the preparation of drugs for preventing and/or treating EV71 infection It can solve the problems of unmentioned and application in the prevention and treatment of enterovirus type 71, and achieve the effect of safe and effective toxic and side effects, alleviating the pain of treatment and improving the quality of treatment.

Inactive Publication Date: 2013-05-08
WUHAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although ganoderma acid has been reported in anti-liver damage, the anti-viral effect on coxsackie virus has not been reported before, and the prevention and treatment of enterovirus 71 (EV71), which is more popular and highly pathogenic, The therapeutic effect has not yet been mentioned and applied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection
  • Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection
  • Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Toxicity test of Ganoderma acid Lanosta-7,9(11),24-trien-3-one15,26-dihydroxy on host cells (MTT method)

[0022] After 24-48 hours of culture, when the RD cells are almost covered with a single layer, the culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. Dilute the Lanosta-7,9(11),24-trien-3-one15,26-dihydroxy stock solution with cell culture medium and configure five concentration gradients, then add different concentrations of drugs and discard the supernatant 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (without adding drugs, only culture medium), and then add 100 μl of cell culture medium to each well, place at 37 ° C, cell culture In the chamber, after culturing for 48 hours, add 20ul of MTT solution (5mg / ml prepared in PBS, pH=...

Embodiment 2

[0026] Example 2: Determination of half infection dose (TCID50) of cells by EV71

[0027] Transfer the RD cells cultured into a single layer to a 96-well cell culture plate, and place them in a cell culture incubator for 18-24 hours. The virus liquid was serially diluted 10 times with the maintenance solution (10 -1 …10 -8 ). Discard the culture medium in each well of RD cultured into a monolayer, wash each well with PBS 3 times, add 100 μl of virus solution of different concentrations to each well, absorb at 37°C for 1.5 h, discard the virus dilution solution, and add 100 μl to each well Maintenance solution, 10 repetitions for each concentration, set normal cell control wells. The cytopathic changes (CPE) in each well were observed daily for 3 consecutive days, and the CPE conditions were recorded. The titer of the virus was then calculated by the following formula.

[0028] PD / [log(dilutionbove50%)-log(dilutionbelow50%)]=[(%nextbove50%)-50%] / [(%nextabove50%)-(%nextbelo...

Embodiment 3

[0030] Example 3: Experiment of the antiviral effect of Ganoderma acid Lanosta-7,9(11),24-trien-3-one15,26-dihydroxy on EV71

[0031] 1) Preventive effect of Ganoderma acid Lanosta-7,9(11),24-trien-3-one15,26-dihydroxy on EV71 virus infection

[0032] After 24-48 hours of culture, when the RD cells are almost covered with a single layer, the culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. The drug was diluted step by step with cell culture medium. After dilution, add different concentrations of drugs into the cell culture wells where the supernatant was discarded, 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (no virus, no drug, only culture solution) and Virus control wells (no drug, virus, culture medium). After drug incubation for 1 hour, discard...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy in preparation of medicaments for preventing and / or treating enterovirus 71 infection. The invention confirms that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good antiviral effect in in-vitro enterovirus 71 (EV 71) infection cell tests. Meanwhile, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxyhas certain killing effect on enterovirus 71 (EV 71), can prevent enterovirus 71 (EV 71) infection, has good treating effect on enterovirus 71 (EV 71) infected cells, has good inhibition effect on viral replication, and has more significant effect than a positive control medicament of ribavirin. In addition, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good inhibition effect on inflammation responses caused by enterovirus 71 (EV 71), which reveals that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has the prospect of being developed into anti-enterovirus 71 (EV 71) medicaments.

Description

technical field [0001] The invention relates to the field of antiviral drugs, and relates to ganoderma acid C 30 h 46 o 3 (Lanosta-7,9(11), 24-trien- 3-one 15,26-dihydroxy, namely 7,9(11), 24-trien-3-one 15,26-dihydroxysterane triterpene) The new application of the invention, specifically its application in the preparation of medicines for the treatment and / or prevention of enterovirus 71 (EV71) infection. Background technique [0002] Enterovirus 71 (human enterovirus 71, EV71) is a member of the Picornaviridae Enterovirus genus, which was first isolated in 1969 from fecal samples of infants with central nervous system diseases in California. Usually EV71 infection will cause hand, foot and mouth disease, which is mild and mostly self-limiting, which is difficult to distinguish from hand, foot and mouth disease caused by Coxsackie A16. In addition, EV71 can also cause aseptic meningitis, brainstem encephalitis, acute flaccid paralysis, acute cardiopulmonary dysfunction ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/575A61P31/14
Inventor 吴建国张文婧陶君彦邬开朗金晶朱应
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com